KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBITDA (2016 - 2025)

Historic EBITDA for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$60.2 million.

  • Supernus Pharmaceuticals' EBITDA fell 24746.24% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 16233.19%. This contributed to the annual value of $81.7 million for FY2024, which is 164993.36% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its EBITDA stood at -$60.2 million for Q3 2025, which was down 24746.24% from $12.1 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' EBITDA's 5-year high stood at $40.8 million during Q3 2024, with a 5-year trough of -$60.2 million in Q3 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' median EBITDA value was $8.1 million (recorded in 2023), while the average stood at $7.9 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBITDA crashed by 25500.62% in 2023, and later skyrocketed by 224909.64% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' EBITDA (Quarter) stood at $6.1 million in 2021, then skyrocketed by 463.04% to $34.3 million in 2022, then crashed by 102.9% to -$996000.0 in 2023, then skyrocketed by 2249.1% to $21.4 million in 2024, then crashed by 381.39% to -$60.2 million in 2025.
  • Its EBITDA stands at -$60.2 million for Q3 2025, versus $12.1 million for Q2 2025 and -$10.3 million for Q1 2025.